Characterization of the class i-restricted GP100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2541-2551

  Walker, Edwin B ^a,b   Miller, William ^a   Haley, Daniel ^a   Floyd, Kevin ^a   Curti, Brendan ^a   Urba, Walter J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100 209-2M; MELANOMA VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; SENTINEL LYMPH NODE;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC MEMORY; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MELANOMA; MEMBRANE GLYCOPROTEINS; SENTINEL LYMPH NODE BIOPSY;

EID: 65249121907     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2806     Document Type: Article

References (50)

1. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation ofa synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321 -7.
2. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005;175: 6169-76.
3. Ayyoub M, Zippelius A, Pittet MJ, et al. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003;9:669 -77.
4. Speiser DE, Romero P. Toward improved immuno- competence of adoptively transferred CD8+ T cells. J Clin Invest 2005;115:1467-9.
5. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
6. Rosenberg SA,Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
7. Yamshchikov GV, Barnd DL, Eastham S, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001;92:703-11.
8. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macro- phage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21: 4016-26.
9. Smith JW, 2nd, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003;21:1562-73.
10. Walker EB, Haley D, Miller W, et al. gp100(209-2M) peptide immunization of human lymphocyte antigen- A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ Tcells. Clin Cancer Res 2004;10: 668-80.
11. Perfetto SP, Chattopadhyay PK, Roederer M. Seven- teen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004;4:648-55.
12. Bagwell CB. Hyperlog-a flexible log-like transform for negative, zero, and positive valued data. Cytometry A 2005;64:34-42.
13. Petrausch U, Haley D, Miller W, Floyd K, Urba WJ, Walker E. Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A 2006;69:1162-73.
14. Tung JW, Parks DR, Moore WA, Herzenberg LA, Herzenberg LA. New approaches to fluorescence compensation and visualization of FACS data. Clin Immunol 2004;110:277-83.
15. Walker EB, Haley D, Petrausch U, et al. Phenotype and functional characterization of long-term gp100- specific memory CD8+ Tcells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res 2008;14:5270-83.
16. Veiga-Fernandes H,Walter U, Bourgeois C, McLean A, Rocha B. Response of naive and memory CD8+Tcells to antigen stimulation in vivo. Nat Immunol 2000;1:47-53.
17. Busch DH, Pamer EG. Tcell affinity maturation by selective expansion during infection. J Exp Med 1999; 189:701-10.
18. Slifka MK,Whitton JL. Functional avidity maturation ofCD8(+) Tcells without selection of higher affinity TCR. Nat Immunol 2001;2:711 -7.
19. Cawthon AG, Alexander-Miller MA. Optimal coloc- alization of TCR and CD8 as a novel mechanism for the control off unctional avidity. J Immunol 2002;169: 3492-8.
20. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
21. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-24.
22. van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol 2002;23:586-91.
23. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003;101:4260-6.
24. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier Ra, Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006;211:236-54.
25. Takata H,Takiguchi M. Three memory subsets of hu- man CD8+ Tcells differently expressing three cytolytic effector molecules. J Immunol 2006;177:4330-40.
26. Romero P, Zippelius A, Kurth I, et al. Four functionally distinct populations of human effector- memory CD8+ T lymphocytes. J Immunol 2007; 178:4112-9.
27. Kim R, Emi M, Tanabe K, Arihiro K. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 2006;7: 1006-16.
28. Jones CM, Cose SC, Coles RM, et al. Herpes sim-plexvirustype1- specificcytotoxic T-lymphocyte arming occurs within lymph nodes draining the site of cutaneous infection. J Virol 2000;74:2414 - 9.
29. Flynn KJ, Belz GT, Altman JD, Ahmed R,Woodland DL, Doherty PC.Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998; 8:683-91.
30. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-ǎ- secreting cells inducing CD4+CD25+ regulatoryTcell proliferation. J Exp Med 2005;202:919-29.
31. Ito M, MinamiyaY, Kawai H, et al. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006;176:5637-43.
32. Chen Q, Daniel V, Maher DW, Hersey P. Production ofIL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994;56:755-60.
33. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
34. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD8+ Tcells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005; 102:9571 -6.
35. Van Epps HL, Terajima M, Mustonen J, et al. Long- lived memory T lymphocyte responses after hantavirus infection. J Exp Med 2002;196:579-88.
36. Lechner F, Wong DK, Dunbar PR, et al. Analysis ofsuccessful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512.
37. Sinclair E, Black D, Epling CL, et al. CMV antigen- specific CD4+ and CD8+ T cell IF Ngamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol 2004; 17:445-54.
38. Janssen EM, Lemmens EE,Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ Tcells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852-6.
39. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 Tcell memory. Science 2003;300:337-9.
40. Sun JC, Bevan MJ. Defective CD8 Tcell memory following acute infection without CD4 Tcell help. Science 2003;300:339-42.
41. Klenerman P, Hill A. Tcells and viral persistence: lessons from diverse infections. Nat Immunol 2005;6: 873-9.
42. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003;77:4911 -27.
43. Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ. Maintenance, loss, and resurgence of Tcell responses during acute, protracted, and chronic viral infections. J Immunol 2004;172:4204-14.
44. den Boer AT, van Mierlo GJ, Fransen MF, MeliefCJ, Offringa R, Toes RE. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 2004;172: 6074 - 9.
45. Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function ofhuman tumor-specific CD8 T cellsin melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-73.
46. Anichini A,Vegetti C, Mortarini R. The paradox of T cell-mediated antitumor immunity in spite of poor clin- ical outcome in human melanoma. Cancer Immunol Immunother 2004;53:855-64.
47. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007;25:171 -92.
48. Sun JC, Williams MA, Bevan MJ. CD4+ Tcells are required for the maintenance, not programming, of memory CD8+ Tcells after acute infection. Nat Immunol 2004;5:927-33.
49. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augment- ed by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174: 2591 -601.
50. Slingluff CL, Jr., Petroni GR, Olson W, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008;26:4973-80. Epub 2008 Sep 22.